Bio-Rad Laboratories is facing financial turbulence as it grapples with a 59.7% drop in stock value over the past five years, exacerbated by a recent acquisition of stilla Technologies and the launch of new ddPCR platforms. The company reported a net income of $720 million for 2025, yet its stock has declined sharply by 14.9% in the past week. An impairment charge of $172.8 million on purchased intangibles and a projected revenue growth of just 0.5% to 1.5% signal ongoing struggles, while trading at a 38.3% discount compared to its estimated intrinsic value of $416.07.
“stilla Technologies · is · acquired by · Bio-Rad”
“QX Continuum and QX700 Series ddPCR platforms · are · recently launched and expanded by · Bio-Rad”
“Bio-Rad Laboratories · closed at · US$256.56”
“Bio-Rad Laboratories · declined over 7 days · 14.9%”
“Bio-Rad Laboratories · declined over 30 days · 18.2%”
“Bio-Rad Laboratories · declined year to date · 16.0%”
“Bio-Rad Laboratories · declined over 1 year · 7.4%”
“Bio-Rad Laboratories · declined over 3 years · 46.9%”
“Bio-Rad Laboratories · declined over 5 years · 59.7%”
“Bio-Rad Laboratories · scores · 6 out of 6 · in valuation checks”
“Bio-Rad Laboratories · estimated intrinsic value per share · about $416.07”
“Bio-Rad Laboratories · trades at a discount · 38.3% · compared to estimated intrinsic value”